Williams & Novak, LLC PBYI β€” PUMA BIOTECHNOLOGY INC

Ownership history in Williams & Novak, LLC  Β·  5 quarters on record

AI Ownership Summary

Williams & Novak, LLC reported PUMA BIOTECHNOLOGY INC (PBYI) in 5 quarterly 13F filings from 2025 Q1 through 2026 Q2. Peak portfolio weight reached 0.06% in 2026 Q2. The latest visible filing shows PBYI at 0.06% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this PBYI ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Williams & Novak, LLC's position in PUMA BIOTECHNOLOGY INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q2

PBYI was reported at 0.06% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
0.06% in 2026 Q2

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2025 Q1 to 2026 Q2

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

PBYI stock page Williams & Novak, LLC fund profile Williams & Novak, LLC full holdings
How Williams & Novak, LLC held PBYI β€” position size vs. price
% of Fund (quarterly)    PBYI price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
πŸ“‹ Quarterly Holdings History 5 quarters  β–Ύ
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q2 REDUCED β€” β€” β€” 10,489 -150 -1.4% 0.06% $85K 2026-07-08 $8.13
2026 Q1 ADDED β€” β€” β€” 10,639 +79 +0.7% 0.05% $72K 2026-04-21 $7.26
2025 Q4 REDUCED 15.7% +7.4% ❌ 10,560 -1,960 -15.7% 0.05% $63K 2026-02-05 $6.79
2025 Q2 REDUCED 14.9% +47.2% ❌ 12,520 -2,200 -14.9% 0.04% $43K 2025-07-24 $3.40
2025 Q1 INITIATED β€” β€” β€” 14,720 β€” β€” 0.04% $43K 2025-05-15 $3.28

🏒 Other funds also holding PBYI

As of 2026 Q2 β€” sorted by position size

C2C Wealth Management, LLC 3Y 0.15% Baron Wealth Management LLC 3Y 0.08% GAMMA Investing LLC 0.0% ELEVATION WEALTH PARTNERS, LLC 0.0%

FAQ About Williams & Novak, LLC and PBYI

These are the practical questions this page is built to answer before you even open the full history table.

How long has Williams & Novak, LLC reported owning PBYI?

Williams & Novak, LLC reported PBYI across 5 quarterly 13F filings, from 2025 Q1 through 2026 Q2.

What was the largest reported PBYI position in Williams & Novak, LLC's portfolio?

The largest reported portfolio weight for PBYI was 0.06% in 2026 Q2.

What is the latest reported PBYI position on this page?

The most recent filing on this page is 2026 Q2, when Williams & Novak, LLC reported 10,489 shares, equal to 0.06% of portfolio, with an estimated market value of $85K.

What does the chart on this PBYI ownership page compare?

The chart compares Williams & Novak, LLC's quarterly PBYI portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did Williams & Novak, LLC time their PBYI position?

Based on 13F filing dates vs. subsequent PBYI price moves, Williams & Novak, LLC correctly timed 2 out of 4 reported position changes (50%). The annualised alpha on PBYI relative to SPY over the holding period was +77.9%.

← Back to Williams & Novak, LLC Holdings